Health Care

Evaxion Biotech’s AI‑Immunology platform hits 86% precision in a Phase II cancer‑vaccine trial and identifies ERV antigens in glioblastoma, showing scalable, next‑gen personalized oncology solutions.

Explore Zai Lab’s 2026 AGM details: director re‑elections, auditor appointments, shareholder resolutions, and its biopharma growth strategy.

Discover how Annovis Bio is advancing neurodegenerative treatments, focusing on rare Alzheimer’s and Parkinson’s cases while navigating biotech challenges.

Corvus Pharmaceuticals’ newly approved immune‑targeting cancer drug is now widely available in U.S. pharmacies, boosting patient access and provider confidence while positioning the biotech firm for future growth.

Biomea Fusion, Inc. pioneers irreversible small‑molecule drugs for genetically defined cancers—explore its precision‑medicine strategy, market potential, and investor outlook.

Valbiotis SA: exploring nutrition‑based cardiometabolic solutions amid price volatility—why investors are watching its biotech gamble.

Explore how Iovance Biotherapeutics gains a strategic edge in advanced melanoma after Replimune’s regulatory setback—insight into its TIL‑focused immunotherapy and market impact.

Cogent Biosciences’ latest stake‑buying move may reshape biotech competition, impacting its stock volatility and future growth prospects.

ADMA Biologics’ share plunge follows a short‑seller report alleging financial misconduct. Explore how regulatory scrutiny, investor sentiment, and its plasma‑derived therapies could shape a future rebound.

VentriPoint Diagnostics highlights unseen U.S. cardiovascular market shifts, offering investors insight into future growth and strategic opportunities in cardiac tech.